NCT05590455View on ClinicalTrials.gov

Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Tuberculous MeningitisHIV I Infection
Interventions
DRUG

Adalimumab Injection

one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids

Trial Locations (3)

21040-900

RECRUITING

Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ, Rio de Janeiro

Unknown

NOT_YET_RECRUITING

Instituto Nacional de Saude, Maputo

NOT_YET_RECRUITING

Adult Infectious Diseases Centre, University Teaching Hospital, Lusaka

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV